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AbstrAct
background. Many studies have previously revealed evidence of an association between grand multiparity (five or 
more deliveries) and gynaecological cancer. Oestrogen has an impact on cancer formation and the amount of circulating 
oestrogen is significantly higher during pregnancy. Also the lifestyle of grand multiparous women differs somewhat 
from the average population. Considering these factors it is plausible that also non-gynaecological cancers are associated 
with multiparity. The aim of our study was to determine cancer incidence among grand multiparous women, with special 
attention to non-gynaecological cancers.
Material and methods. All 102 541 women alive in 1974–2011 and having had at least five deliveries were identified 
in the Finnish Population Register and followed up for cancer incidence through the Finnish Cancer Registry to the end 
of 2011. Standardised incidence ratios (SIRs) were defined as ratios between observed and expected numbers of cases, 
the latter ones based on incidence in the entire Finnish female population.
results. The overall incidence of non-gynaecological cancers was the same as in the reference population (SIR 0.98, 
95% confidence interval 0.90–1.06). The incidence of cancers of the gall-bladder (SIR 1.42, 1.26–1.58), biliary tract 
(1.19, 1.04–1.35) and kidney (1.22, 1.14–1.31) was increased. There were significantly fewer cases than expected of 
urinary bladder cancer (SIR 0.70, 0.61–0.78), lung cancer (0.87, 0.81–0.92), colon cancer (0.94, 0.89–0.99) and all types 
of skin cancers. As a consequence of the decreased incidence of gynaecological cancers (SIR 0.74, 0.71–0.77) and breast 
cancer (0.60, 0.58–0.61), the SIR for cancer overall was 0.84 (0.83–0.85).
conclusion. The study demonstrated that grand multiparous women have a similar overall risk of non-gynaecological 
cancers as other women, despite significant differences in some specific forms of cancer.
a multitude of studies have previously revealed 
strong evidence of an association between grand 
multiparity (five or more deliveries) and gynaeco-
logical cancer. grand multiparous (gm) women are 
known to have decreased incidence of endometrial, 
ovarian and breast cancer, while the incidence of 
cervical cancer may be increased [1–4]. Pregnancies 
and breast feeding periods are a dominant part of the 
reproductive life of gm women, who therefore differ 
markedly from other women as regards lifestyle and 
hormonal environment. oestrogen receptors are 
widely distributed in mammalian tissues and present 
the first step in a pathway where oestrogen affects 
malignant transformation, i.e. through Dna damage 
[5]. new evidence further shows that oestrogen has 
an impact on carcinogenesis in general [6], and also 
specifically, i.e. colon, thyroid and lung cancer have 
been shown to be influenced by sex steroids [7–9].
The risk of cancer is greatly dependent on lifestyle 
factors, which may in many ways be different in 
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multiparous and other women. For instance, mortal-
ity from ischaemic heart disease and diabetes appears 
to be elevated among Finnish gm women [1–4,10]. 
nevertheless, the incidence of non-gynaecological 
cancers in gm women has not been studied to a great 
extent. The findings on risks of non-gynaecological 
cancers are not consistent but there are scattered 
observations on significantly decreased or increased 
incidence of several cancer types. For example, a 
Taiwanese study observed [7] 28% decreased risk for 
colon cancer among women with four or more deliv-
eries as compared to women with only one delivery, 
while a recent Egyptian study observed an odds ratio 
(oR) as low as 0.3 (0.1–0.5) for colorectal cancer 
among women with seven reported pregnancies 
compared with women who reported 1–3 deliveries 
[11]. In a meta-analysis by Dietrich et al. [12] the 
risk for bladder cancer among ever parous women 
was one third lower than among nulliparous women, 
and the oR for gm women was 0.74, although with 
a rather wide CI (0.35–1.57). In a Chinese study 
[13] the risk for gall bladder cancer was increased for 
women with five deliveries as compared with women 
with one delivery (oR 2.20, 95% CI 1.01–4.66). In 
a cohort study by Kabat et al. the risk for renal cancer 
increased with increasing parity and HR for gm 
women was 2.41 (95% CI 1.27–4.59) compared to 
nulliparous women [14].
The aim of this study was to obtain more informa-
tion on the long-term risks and benefits of multiple 
pregnancies. a secondary aim was to update the results 
related to gynaecological cancers among the Finnish 
gm population reported about 10 years ago [1–4].
Material and methods
The study cohort consisted of all Finnish women 
having their fifth child before 2011, and who had not 
emigrated or died before 1974. The cohort was drawn 
from the Finnish Population Register, and consisted 
of 104 896 women. Those born abroad (n  2355) 
were excluded because the data on their parity his-
tory may be unclear. Thus the final size of the cohort 
was 102 541 women.
For calculation of person-years of follow-up the 
starting point was 1 January 1974 or birth of the fifth 
child, whichever came later, and the end-point was 
the date of emigration or death, or 31 December 
2011, whichever occurred first. The total number for 
person-years of follow-up was 2 672 587 (Table I). 
The follow-up could not start before 1974 because 
the mother-child links in the Finnish population reg-
ister were not created if the mother had died before 
october 1973.
Information on cancer cases in the cohort was 
obtained from the national population-based Finnish 
Cancer Registry, using record linkage based on per-
sonal identity codes. The cancer cases were classified 
according to the main topographic categories, using 
the ICD-10 classification system (Table II).
The expected numbers of each cancer type were 
calculated by multiplying the number of person-
years of the gm women in each five-year age cate-
gory and calendar period (1974–1980, 1981–1987, 
1988–1993, 1994–1999, 2000–2005, 2006–2011) by 
the cancer incidence rate among all Finnish women 
in the same age and calendar time category. SIRs 
were defined as the ratios between the observed and 
expected numbers of cases. Confidence intervals 
(CIs) for the SIRs were based on the Poisson distri-
bution of the observed number of cases. The analyses 
were further stratified according to age at follow-up 
(20–29 years, 30–39 years, 40–49 years, 50–59 years, 
60–69 years, 70–79 years and 80 years or older) age 
at first birth ( 20 years, 20–24 years, 24–30 years 
and 30 years or older) and time since fifth birth 
(0–4.99 years, 5–9.99 years and 10 years or longer).
Results
During the follow-up period 16 322 cancers were 
diagnosed in the gm cohort.
of the non-gynaecological cancers (Table II), sig-
nificantly decreased SIRs were observed for lung 
cancer (SIR 0.87, 95% CI 0.81–0.92), bladder can-
cer (SIR 0.70, 95% CI 0.61–0.78) and cancer of 
unknown origin (0.62, 95% CI 0.55–0.68). The rates 
for all types of skin cancer were also significantly 
decreased. The risk of skin melanoma was especially 
low during the first 10 years after the fifth birth (SIR 
0.38, 95% CI 0.21–0.63).
Table I. number of women (n) and person-years in the gm-
cohort in each age group, follow-up period and listed according 
to age at first birth. The numbers in n column refer to the age in 
the beginning of follow-up. The respective numbers of person-
years refer to the dynamic age during follow-up (i.e. a woman may 
contribute person-years to several categories).
years n Person-years
age at follow-up 20–29 8 940 19 140
30–39 35 134 217 805
40–49 34 556 493 342
50–59 21 296 667 342
60–69 2 614 645 106
70–79 1 459 789
80 – 170 063
Time since fifth delivery 0–4.99 42 201 180 921
5–9.99 14 276 201 152
10 46 064 2 290 513
age at first birth  20 20 364 518 453
20–25 53 264 1 421 398
26–29 22 961 591 576
30 5 952 141 160


































age at follow-up. For instance, the SIRs in age cat-
egory 80  years were 0.69 (95% CI 0.62–0.76) for 
breast cancer, 0.80 (95% CI 0.65–0.96) for endome-
trial cancer, 0.85 (95% CI 0.67–1.07) for ovarian 
cancer and 1.45 (95% CI 1.00–2.03) for cervical 
cancer. The SIR for cervical cancer according to 
age at follow-up followed a U-shaped curve, with the 
lowest SIR (1.02, 0.81–1.26) in age category 60–69 
years.
as regards most cancers there was no significant 
variation in SIRs according to age at first birth, time 
of follow-up since fifth birth and age at follow-up, a 
few exceptions were nevertheless noted. The SIR for 
renal cancer was high among women with low or 
high age at first birth (Figure 1). Similar pattern for 
Significantly increased SIRs were observed as 
regards cancer of the gall-bladder (SIR 1.42, 95% 
CI 1.26–1.58), extra- and intrahepatic bile ducts 
(SIR 1.19, 95% CI 1.04–1.35), kidney (SIR 1.22, 
95% CI 1.14–1.31) and thyroid gland (SIR 1.31, 
95% CI 1.19–1.43).
The incidences of breast cancer, endometrial 
cancer and ovarian cancer were markedly decreased, 
while that of cervical cancer was increased (Table III). 
among lesions registered by the Finnish Cancer 
Registry but not regarded as cancers, the SIRs for in 
situ lesions of breast cancer and borderline tumours 
of the ovary were significantly below 1.0 and the SIR 
for precursor lesions of cervical cancers was signifi-
cantly above 1.0. The SIRs increased with increasing 
Table II. observed (oBS) and expected (EXP) numbers of non-gynaecological cancer cases, and 
standardized incidence ratios (SIR) with 95% confidence intervals (CI), among grand multiparous 
women in Finland 1974–2011, by site.
ICD-10 Site oBS EXP SIR 95% CI
all sites 16 322 19 417 0.84 0.83–0.85
all sites, excluding breast cancer 
and gynaecological cancers
11 144 11 402 0.98 0.90–1.06
C00 lip 70 66 1.07 0.83–1.35
C01–02 Tongue 55 70 0.79 0.59–1.02
C03–06 mouth, other 73 73 1.00 0.78–1.25
C07–08 Salivary glands 41 42 0.97 0.69–1.31
C09–14 Pharynx 30 36 0.82 0.56–1.17
C15 oesophagus 147 162 0.91 0.77–1.06
C16 Stomach 746 731 1.02 0.95–1.09
C17 Small intestine 69 63 1.10 0.85–1.39
C18 Colon 1180 1257 0.94 0.89–0.99
C19–21 Rectum, rectosigmoid, anus 684 713 0.96 0.89–1.03
C22–24 liver, gallbladder and biliary tract 696 563 1.24 1.06–1.42
Liver 183 172 1.06 0.91–1.22
Gallbladder 294 207 1.42 1.26–1.58
Intra- and extrahepatic bile ducts 219 184 1.19 1.04–1.35
C25 Pancreas 830 809 1.03 0.96–1.09
C26 other digestive organs 71 65 1.09 0.85–1.37
C30–31 nose, sinuses 29 30 0.96 0.65–1.38
C32 larynx, epiglottis 32 26 1.23 0.84–1.73
C33–34 lung, trachea 888 1019 0.87 0.81–0.92
C40–41 Bone 21 21 1.02 0.63–1.55
C43 Skin melanoma 395 527 0.75 0.68–0.82
C44 Skin, squamous cell carcinoma 647 721 0.90 0.83–0.96
C45 mesothelioma 29 37 0.78 0.52–1.11
C46 Kaposi sarcoma 7 10 0.68 0.27–1.40
C47 autonomic nervous system 2 5 0.38 0.04–1.32
C48–49 Soft tissues 124 127 0.98 0.81–1.15
C64–65 Kidney 781 638 1.22 1.14–1.31
C66–68 Bladder, ureter, urethra 244 349 0.70 0.61–0.78
C69 Eye 52 51 1.06 0.80–1.38
C70–72, D32–33, D42–43 Brain, central nervous system 702 751 0.93 0.87–1.00
C73 Thyroid gland 436 334 1.31 1.19–1.43
C74–75 other endocrine glands 25 18 1.37 0.88–2.01
C76, C80 Cancer of unknown origin 354 574 0.62 0.55–0.68
C81 Hodgkin lymphoma 48 56 0.86 0.63–1.13
C82–85, C96 non-Hodgkin lymphoma 708 727 0.97 0.90–1.04
C90 myeloma 315 299 1.05 0.94–1.17
C91–95 leukaemia 394 399 0.99 0.89–1.08
not included above
Basal cell carcinoma of the skin 4120 5048 0.82 0.79–0.84


































SIRs according to age at first birth was not seen in 
any other cancer form. Concerning stomach cancer, 
the overall incidence in the cohort was similar to that 
in the reference population, but there was a pecu-
liarly very low risk in the follow-up period of 5–9.99 
years after the fifth birth, with only one case observed 
versus 11.1 expected (SIR 0.09, 95% CI 0.00–0.49). 
In turn, a four-fold statistically significant increase in 
the incidence of multiple myeloma was seen during 
the first five-year follow-up period after the fifth 
birth, based, however, on only four observed cases 
(SIR 4.41, 95% CI 1.20–11.28), while the incidence 
of myeloma among gm women in later follow-up 
was close to that in the reference population.
Discussion
The total incidence of non-gynaecological cancer 
was virtually the same as in the reference population. 
However, the incidence of some cancer types among 
gm women was significantly different compared 
with that in Finnish women in general. a decreased 
SIR was observed in cancers of the lung, bladder and 
skin, increased SIRs for kidney, thyroid, bile duct and 
gall-bladder. The total cancer incidence was 
decreased, mostly because of a decreased incidence 
of all gynaecological cancers and breast cancer.
This study is one of the largest gm women study 
ever done. It was conducted in a country with registers 
containing reliable data on births and cancer diagno-
ses. The personal identity codes given to every Finn 
since 1967 guarantee accurate record linkage. The 
reporting and diagnostic praxis is virtually the same 
everywhere in Finland. as we only had indirect infor-
mation on lifestyle factors, our possibilities to evaluate 
the potential effects of confounders are incomplete.
a large part of the gm cohort belongs to the 
laestadian movement within the lutheran church in 
Finland, which is especially common in the northern 
parts of the country. among members of the laes-
tadian movement the use of contraceptives is strictly 
forbidden, alcohol consumption is rare, but smoking 
is permitted. grand multiparous women are more 
likely to be married than women in the reference 
population, and the income of Finnish gm families 
may be satisfactory, as an allowance is paid by the 
state for each child [15]. multiple pregnancies are 
associated with significant weight gain followed by 
obesity and increased mortality from type II diabetes 
mellitus [10,16].
Smoking was predicted to cause 82% of all lung 
cancers, 25% of bladder cancers and 7% of kidney 
cancers of Finnish women in 2000 [17]. The low SIR 
for lung cancer (0.86) in this cohort fits with the fact 
that smoking among Finnish gm women is less fre-
quent than among other women [18]. although there 
is one observation of a decreased incidence of lung 
cancer among non-smoking gm women (hazard 
ratio 0.50, 95% CI 0.28–0.88) compared with non-
smoking women with one or two children [9,19], it 
Table III. observed (oBS) and expected (EXP) numbers of breast cancer and gynaecological cancer 
cases, and standardized incidence ratios (SIR) with 95% confidence intervals.
ICD–10 Site oBS EXP SIR 95% CI
C50 Breast 3137 5265 0.60 0.58–0.61
C51–57 gynaecological cancers 2041 2751 0.74 0.71–0.77
C53 Cervix 356 289 1.23 1.11–1.36
C54 Endometrium 864 1352 0.63 0.58–0.66
C55 Uterus, other 23 27 0.86 0.55–1.29
C56 ovary 594 847 0.70 0.65–0.75
C51–52, C57 other female genitals 222 235 0.95 0.83–1.07
Premalignant lesions:
Breast; carcinoma in situ 113 220 0.51 0.42–0.61
Cervix cancer; precursor 419 354 1.18 1.07–1.30
ovary, borderline tumour 114 148 0.77 0.64–0.91
Figure 1. Standardized incidence ratio (SIR) of renal cancer, 
with 95% confidence intervals, according to age at first birth.

































appears unlikely that pregnancies could offer protec-
tion against lung cancer to any great extent.
although smoking is an important risk factor as 
regards bladder cancer, more than half of the inci-
dence is attributed to other aetiological factors [17]. 
The low SIR for bladder cancer (0.70) in this study 
and the finding by Hinkula et al. (2005) of decreased 
bladder cancer mortality [standardised mortality 
ratio (SmR) 0.59, 95% CI 0.41–0.81] [10] among 
Finnish gm women are so low that the decrease 
cannot be attributable to scarce smoking alone. The 
risk reduction might be explained by the hypothesis 
that pregnancy-related changes in sex steroids antag-
onise oncogenes in bladder tissue [12,20].
Besides smoking, obesity is an established risk 
factor of renal cancer [21]. In a previous Canadian 
study a BmI- and smoking-adjusted odds ratio of 
2.41 (95% CI 1.27–4.59) was reported for renal 
cancer in gm women [14]. We also observed an 
increased incidence of renal cancer (SIR 1.22), but 
it is difficult to estimate the sum effect of the risk 
increasing bias due to obesity and the risk decreasing 
bias due to less smoking.
We observed a U-shaped curve for the relative 
risk of renal cancer according to age at first birth 
(Figure 1). The observation of an increased risk 
among women with first birth at a young age is in 
line with previous findings [22,23], but the increased 
risk among women with first birth at a relatively old 
age has not been reported before. There is some 
experimental evidence of an oestrogen effect in renal 
cancer development [24], and also evidence that 
physiological changes in renal function during preg-
nancy might affect the risk of cancer [25,26].
Despite the fact that gm women are more obese 
and should therefore be at an increased risk of colon 
cancer [27], our results demonstrate that the gm 
women had a slightly decreased incidence of this dis-
ease. The colonic epithelium is affected by ovarian 
hormones [28], but the results of large epidemio-
logical studies have been conflicting regarding the 
association between colon cancer and parity. Some 
studies have revealed a decreased risk with increasing 
parity [7,29,30]. When taking the bias due to obesity 
into account, our SIR (0.94) may be too high and 
actually accord with the hypothesis of increasing 
parity decreasing colon cancer incidence.
In the present study we found a 37% increase in 
the incidence of biliary tract cancer in gm women. 
a Chinese study revealed an approximately two-fold 
increase in BmI-adjusted risk of gall-bladder cancer 
among gm women, while the respective risk as 
regards bile duct cancer was decreased [13,31]. a 
similar risk reduction as regards bile duct cancer was 
not seen in our study. obesity and cholelithiasis are 
known to increase the risk of gall-bladder cancer 
[32,33]. High levels of endogenous oestrogens have 
also been associated with an increased risk [34].
We found an increased SIR for thyroid cancer in 
the present study. as mentioned earlier, approxi-
mately one third of the study cohort comes from the 
northern part of Finland, with exceptionally high 
diagnostic activity concerning thyroid malignancies 
since the 1980s, and as a consequence a higher inci-
dence of thyroid cancer. as a result of this surveil-
lance bias, our risk estimate for thyroid cancer may 
be somewhat too high. Similar surveillance bias is not 
likely to confound risk estimates of other cancers. 
High levels of oestrogens, human chorionic gonado-
trophin (hCg) and thyroid-stimulating hormone 
(TSH) during pregnancy are responsible for direct 
thyroid stimulation and may promote tumour growth 
[35,36]. The increased risk in the first few years post-
partum followed by a downward trend, as reported 
in several studies [37–39], was not observed in our 
study. one possibility is that surveillance bias affected 
the earlier studies.
The incidence of multiple myeloma in our study 
was increased during the first five years after the 
fifth delivery. This finding may well be due to chance, 
but it might also be a result of transient immune 
suppression during pregnancy [40].
In the present study, the SIR for melanoma was 
0.75 (95% CI 0.68–0.82). Data from 10 previous 
studies also suggest that grand multiparity may 
decrease the risk of melanoma (pooled oR 0.73, 
95% CI 0.51–1.04 for gm women) [41]. Sun 
exposure, especially sunburn, elevates the risk of 
melanoma [42] and it is natural that women with big 
families do not have much time for sunbathing. In 
a recent meta-analysis [43] it appeared that the 
negative association between parity and melanoma 
is confounded by socioeconomic status.
It is known that cumulative sun exposure is a 
predisposing factor as regards basal cell cancer and 
squamous cell skin cancer [44]. The overall incidence 
of all skin cancers is lower in the northern parts of 
Finland than elsewhere, which may explain the 
decreased risk of skin cancers. an alternative 
explanation for the low risk of basal cell skin cancer 
may be the inverse association suggested between 
BmI and basal cell carcinoma [45], which may be 
related to increased oestrogen production in adipose 
tissue [46].
The risk estimates for gynaecological cancers and 
breast cancer were not the main focus of the current 
study. These cancer risks have been studied in detail 
in connection with a similar register-based cohort 
and published in several papers [1–4,47,48]. The 
current cohort simply offers a longer follow-up 
period for the women in the old cohort and adds to 
it about 25 000 women who had their fifth child after 


































1997. The new analyses provide slightly higher SIRs 
than published earlier concerning breast (SIR 0.60 
vs. 0.55 [1]), endometrial (0.63 vs. 0.57 [2]) and 
ovarian (0.70 vs. 0.64 [4]) cancers because of the 
larger fraction of person-years in the older age cat-
egories in the current follow-up. The SIRs for both 
breast and gynaecological cancers were all higher 
among the present gm women than among women 
with 10 or more deliveries in a recent study of ours 
[49], indicating that further deliveries provide fur-
ther protection. a similar phenomenon – decreased 
cancer risk with increasing number of births – was 
also observed in an earlier study on Finnish gm 
women [1]. For cervical cancer, in opposite to other 
gynaecological cancers, the SIR increases with 
increasing parity, because its aetiology largely con-
sists of human papilloma virus infection. multipar-
ity may also be an independent risk factor [3]. In 
our study the SIR was 1.23, i.e. higher than in the 
older Finnish study by Hinkula et al. (1.13 [3]), 
most likely caused by larger fraction of person-years 
in the age categories of 70  years with SIRs 1.3 or 
higher.
This study, on a national cohort of 103 000 gm 
women, shows that these women have a lowered can-
cer risk, mostly as a result of low gynaecological and 
breast cancer rates. The results regarding most other 
cancer sites suggest that malignant transformation is 
generally not related to reproductive history and 
therefore there is no need to plan more intensive 
cancer screening procedures for gm women than for 
of other women. as comprehensive adjustment for 
cofactors, such as obesity and smoking was not pos-
sible in this study setting, further research is needed 
to determine the effect of grand multiparity alone on 
some non-gynaecological cancers. 
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